Alkermes Plc Share Price (NASDAQ: ALKS)

$29.75

▲

0.69

(2.37%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Alkermes Plc Stock chart to analyse performance

Alkermes Plc stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$29.33
Today's High:$29.95
$29.75
1.41%
Downside
Day's Volatility :2.07%
Upside
0.67%
52 Weeks Low:$25.56
52 Weeks High:$36.45
$29.75
14.08%
Downside
52 Weeks Volatility :29.88%
Upside
18.38%

Alkermes Plc Stock Returns

Period	Alkermes Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-0.5%	5.1%	0.0%
6 Months	-16.24%	-6.4%	0.0%
1 Year	6.44%	-11.8%	0.0%
3 Years	18.01%	5.9%	-7.8%

Alkermes Plc Key Stats

Check Alkermes Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$29.06
Open	$29.33
Today's High	$29.95
Today's Low	$29.33
Market Capitalization	$4.8B
Today's Volume	$1.4M
52 Week High	$36.45
52 Week Low	$25.56
Revenue TTM	$1.5B
EBITDA	$403.3M
Earnings Per Share (EPS)	$2.07
PE Ratio	14.04
Profit Margin	23.15%
Quarterly Earnings Growth YOY	-0.02%
Return On Equity TTM	23.94%

Stock Returns calculator for Alkermes Plc Stock including INR - Dollar returns

The Alkermes Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Alkermes Plc investment value today

Current value as on today

₹1,10,756

Returns

₹10,756

(+10.76%)

Returns from Alkermes Plc Stock

₹6,440 (+6.44%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Alkermes Plc Stock

100%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Alkermes Plc Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Alkermes Plc

Name
Holdings %
Name
Holdings %
BlackRock Inc
16.60%
Vanguard Group Inc
11.21%
T. Rowe Price Associates, Inc.
6.08%
State Street Corp
4.86%
Renaissance Technologies Corp
3.48%
JPMorgan Chase & Co
3.17%

Analyst Recommendation on Alkermes Plc Stock

Rating

Trend

Buy

63%Buy

31%Hold

5%Sell

Based on 19 Wall street analysts offering stock ratings for Alkermes Plc(by analysts ranked 0 to 5 stars)

Alkermes Plc Share Price Target

What analysts predicted

Upside of 39.5%

Target:

$41.50

Current:

$29.75

Alkermes Plc share price target is $41.50, a slight Upside of 39.5% compared to current price of $29.75 as per analysts' prediction.

Alkermes Plc Stock Insights

Price Movement
In the last 1 month, ALKS stock has moved up by 6.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 306.51M → 390.65M (in $), with an average increase of 21.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 22.46M → 87.09M (in $), with an average increase of 74.2% per quarter
ALKS vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 53.8% return, outperforming this stock by 37.2%

Alkermes Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.2B	↑ 7.01%
Net Income	$-196.6M	↑ 41.14%
Net Profit Margin	-16.79%	↓ 4.06%

	FY20	Y/Y Change
Revenue	$1.0B	↓ 11.29%
Net Income	$-110.9M	↓ 43.62%
Net Profit Margin	-10.67%	↑ 6.12%

	FY21	Y/Y Change
Revenue	$1.2B	↑ 13.0%
Net Income	$-48.2M	↓ 56.55%
Net Profit Margin	-4.1%	↑ 6.57%

	FY22	Y/Y Change
Revenue	$1.1B	↓ 5.28%
Net Income	$-158.3M	↑ 228.57%
Net Profit Margin	-14.24%	↓ 10.14%

	FY23	Y/Y Change
Revenue	$1.7B	↑ 49.61%
Net Income	$355.8M	↓ 324.78%
Net Profit Margin	21.39%	↑ 35.63%

	FY24	Y/Y Change
Revenue	$1.6B	↓ 6.36%
Net Income	$367.1M	↑ 3.18%
Net Profit Margin	23.57%	↑ 2.18%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$350.4M	↓ 7.18%
Net Income	$36.8M	↓ 67.34%
Net Profit Margin	10.51%	↓ 19.37%

	Q2 FY24	Q/Q Change
Revenue	$399.1M	↑ 13.92%
Net Income	$91.4M	↑ 148.07%
Net Profit Margin	22.89%	↑ 12.38%

	Q3 FY24	Q/Q Change
Revenue	$378.1M	↓ 5.26%
Net Income	$92.4M	↑ 1.12%
Net Profit Margin	24.43%	↑ 1.54%

	Q4 FY24	Q/Q Change
Revenue	$430.0M	↑ 13.71%
Net Income	$146.5M	↑ 58.59%
Net Profit Margin	34.07%	↑ 9.64%

	Q1 FY25	Q/Q Change
Revenue	$306.5M	↓ 28.72%
Net Income	$22.5M	↓ 84.67%
Net Profit Margin	7.33%	↓ 26.74%

	Q2 FY25	Q/Q Change
Revenue	$390.7M	↑ 27.45%
Net Income	$87.1M	↑ 287.72%
Net Profit Margin	22.3%	↑ 14.97%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$990.6M	↑ 7.92%

	FY20	Y/Y Change
Profit	$860.4M	↓ 13.14%

	FY21	Y/Y Change
Profit	$976.4M	↑ 13.48%

	FY22	Y/Y Change
Profit	$893.7M	↓ 8.47%

	FY23	Y/Y Change
Profit	$1.4B	↑ 57.81%

	FY24	Y/Y Change
Profit	$1.3B	↓ 6.95%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$291.7M	↓ 5.09%

	Q2 FY24	Q/Q Change
Profit	$337.7M	↑ 15.74%

	Q3 FY24	Q/Q Change
Profit	$315.0M	↓ 6.7%

	Q4 FY24	Q/Q Change
Profit	$367.9M	↑ 16.77%

	Q1 FY25	Q/Q Change
Profit	$257.3M	↓ 30.05%

	Q2 FY25	Q/Q Change
Profit	$341.2M	↑ 32.6%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$72.1M	↓ 27.4%
Investing Cash Flow	$-141.8M	↑ 539.03%
Financing Cash Flow	$6.8M	↓ 517.59%

	FY20	Y/Y Change
Operating Cash Flow	$82.8M	↑ 14.94%
Investing Cash Flow	$-11.5M	↓ 91.91%
Financing Cash Flow	$-2.2M	↓ 132.09%

	FY21	Y/Y Change
Operating Cash Flow	$101.7M	↑ 22.78%
Investing Cash Flow	$-66.2M	↑ 476.64%
Financing Cash Flow	$29.1M	↓ 1439.11%

	FY22	Y/Y Change
Operating Cash Flow	$21.0M	↓ 79.31%
Investing Cash Flow	$-64.5M	↓ 2.51%
Financing Cash Flow	$-1.6M	↓ 105.41%

	FY23	Y/Y Change
Operating Cash Flow	$401.4M	↑ 1807.21%
Investing Cash Flow	$53.4M	↓ 182.67%
Financing Cash Flow	$-289.7M	↑ 18306.23%

	FY24	Y/Y Change
Operating Cash Flow	$439.1M	↑ 9.41%
Investing Cash Flow	$-111.3M	↓ 308.61%
Financing Cash Flow	$-494.1M	↑ 70.56%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$21.1M	↓ 80.32%
Investing Cash Flow	$-40.0M	↑ 90.41%
Financing Cash Flow	$-17.9M	↓ 93.54%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$146.0M	↑ 591.82%
Investing Cash Flow	$51.9M	↓ 229.78%
Financing Cash Flow	$-83.5M	↑ 367.09%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$81.6M	↓ 44.13%
Investing Cash Flow	$-109.3M	↓ 310.86%
Financing Cash Flow	$-111.1M	↑ 33.1%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$190.4M	↑ 133.36%
Investing Cash Flow	$-13.9M	↓ 87.31%
Financing Cash Flow	$-281.7M	↑ 153.5%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$98.8M	↓ 48.1%
Investing Cash Flow	$9.1M	↓ 165.6%
Financing Cash Flow	$747.0K	↓ 100.27%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$150.2M	↑ 52.01%
Investing Cash Flow	$-29.2M	↓ 420.96%
Financing Cash Flow	$405.0K	↓ 45.78%

Alkermes Plc Technicals Summary

Sell

Neutral

Buy

Alkermes Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Alkermes Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alkermes Plc	9.52%	-16.24%	6.44%	18.01%	78.25%
Haleon Plc Spon Ads	-0.41%	-3.35%	-0.91%	55.47%	32.39%
United Therapeutics Corporation	1.94%	-12.81%	-10.25%	40.38%	75.65%
Zoetis Inc.	2.46%	-5.28%	-13.44%	-3.72%	-0.11%
Neurocrine Biosciences Inc.	2.8%	13.62%	-11.44%	26.96%	21.38%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alkermes Plc	14.04	14.04	-1057.29	1.73	0.24	0.1	NA	9.84
Haleon Plc Spon Ads	21.8	21.8	3.15	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.18	12.18	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.74	26.74	2.54	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	40.02	40.02	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alkermes Plc	Buy	$4.8B	78.25%	14.04	23.15%
Haleon Plc Spon Ads	Buy	$44.6B	32.39%	21.8	13.81%
United Therapeutics Corporation	Buy	$14.1B	75.65%	12.18	40.36%
Zoetis Inc.	Buy	$69.0B	-0.11%	26.74	27.83%
Neurocrine Biosciences Inc.	Buy	$13.4B	21.38%	40.02	13.88%

About Alkermes Plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Organization	Alkermes Plc
Employees	1800
CEO	Mr. Richard F. Pops
Industry	Health Technology

Key Management of Alkermes Plc

Name	Title
Mr. Richard F. Pops	Chairman & CEO
Mr. Blair C. Jackson	Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO
Mr. David Joseph Gaffin J.D.	Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
Dr. Craig C. Hopkinson M.D.	Executive VP of Research & Development and Chief Medical Officer
Mr. C. Todd Nichols	Senior VP & Chief Commercial Officer
Mr. Samuel J. Parisi	Interim Principal Accounting Officer & VP of Finance
Mr. Thomas Harvey	Chief Information Officer & Senior VP of IT
Ms. Sandra Coombs	Senior Vice President of Corporate Affairs & Investor Relations
Mr. Stephen Schiavo	Senior VP & Chief Human Resources Officer
Mr. Peter Norman	Senior Vice President of Policy & Government Relations

Important FAQs about investing in ALKS Stock from India :

What is Alkermes Plc share price today?

Alkermes Plc share price today is $29.75 as on August 23, 2025 at 1:29 AM IST at the close of the market. Alkermes Plc share today touched a day high of $29.95 and a low of $29.33.

What is the 52 week high and 52 week low for Alkermes Plc share?

Alkermes Plc share touched a 52 week high of $36.45 and a 52 week low of $25.56. Alkermes Plc stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $29.75, lower by 18.38% versus the 52 week high.

How to invest in Alkermes Plc Stock (ALKS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Alkermes Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alkermes Plc Shares that will get you 0.0504 shares as per Alkermes Plc share price of $29.75 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Alkermes Plc Stock (ALKS) from India?

Indian investors can start investing in Alkermes Plc (ALKS) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Alkermes Plc stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Alkermes Plc share’s latest price of $29.75 as on August 23, 2025 at 1:29 AM IST, you will get 0.3361 shares of Alkermes Plc. Learn more about fractional shares .

What are the returns that Alkermes Plc has given to Indian investors in the last 5 years?

Alkermes Plc stock has given 78.25% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?